Clinical trials
Breast Cancer Invasive clinical trials
Below are recruiting breast cancer invasive clinical trials, each written for real people, not researchers. We’re tracking 717 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07191717RecruitingPhase 2
Imlunestrant and abemaciclib for early ER+ breast cancer
This trial tests whether adding two targeted drugs, imlunestrant and abemaciclib, to your usual hormone therapy can lower the chance of your breast cancer coming back. It is for people with early-stage ER+ breast cancer who have no signs of cancer on scans but have tiny amounts of tumor DNA in their blood (called ctDNA).
Los Angeles, CaliforniaAges 18 years+ - NCT07188246RecruitingPhase 2
Radiation and immunotherapy before chemo for breast cancer
This trial tests a new approach for breast cancer that combines a short course of focused radiation (SBRT) with an injection of the immunotherapy drug pembrolizumab directly into the tumor, followed by standard chemotherapy before surgery. The goal is to see if this combination helps shrink the tumor more effectively before surgery.
London, OntarioAges 18 years+ - NCT06225284RecruitingPhase 2
Chemotherapy with or without hormone drug for premenopausal TNBC
This trial tests whether adding a hormone-blocking drug (GnRH agonist) to standard chemotherapy before surgery helps premenopausal women with triple-negative breast cancer. It aims to improve treatment outcomes by targeting hormones that may fuel tumor growth.
TaipeiAges 18 years+ - NCT07179744Recruiting
Skipping radiation for low-risk node-positive breast cancer
This trial tests whether some women with low-risk breast cancer that has spread to a few lymph nodes can safely skip radiation therapy after surgery. It aims to reduce side effects while keeping the cancer from coming back.
Guangzhou, GuangdongAges 18–70 - NCT07164976RecruitingPhase 1/Phase 2
Ribociclib for advanced HR+ HER2- breast cancer
This trial tests a new combination of ribociclib and anastrozole as a first treatment for advanced hormone receptor-positive, HER2-negative breast cancer that has not been treated before. It may help if you have not received any prior therapy for metastatic disease.
NagoyaAges 18 years+ - NCT05658172Recruiting
Less vs more frequent follow-up after early breast cancer
This trial compares standard follow-up visits versus more intensive follow-up for people with early breast cancer after their main treatment. The goal is to see whether closer monitoring finds problems earlier or improves outcomes.
UlmAges 18–75 - NCT07159451RecruitingPhase 2
Elacestrant for premenopausal women with early breast cancer
This trial tests a new hormone therapy pill, elacestrant, given alone or with another drug to suppress ovarian function before surgery. It's for premenopausal women with early-stage, hormone receptor-positive, HER2-negative breast cancer to see if it can shrink the tumor.
VillejuifAges 18 years+ - NCT07152782RecruitingPhase 2
T-DXd with or without neratinib for HER2+ breast cancer brain metastases
This trial tests whether adding neratinib to T-DXd (trastuzumab deruxtecan) works better than T-DXd alone for women with HER2-positive breast cancer that has spread to the brain. It is for those who have not had these specific drugs before.
ShanghaiAges 18–70 - NCT07150208RecruitingPhase 2
T-DXd with or without Avastin for HER2-low breast cancer that spread to the brain
This trial tests a combination of two targeted drugs (T-DXd and bevacizumab) for people with HER2-low breast cancer that has spread to the brain. It aims to see if adding bevacizumab helps the main drug work better against brain metastases.
ShanghaiAges 18–70 - NCT07146295Recruiting
ICG dye to find sentinel nodes in breast cancer surgery
This trial tests using a green dye called ICG (indocyanine green) during breast cancer surgery to find the first lymph nodes (sentinel nodes) that cancer may have spread to. It aims to help doctors locate these nodes more accurately, and is for people with early-stage breast cancer that has not yet spread to the lymph nodes.
AlkmaarAges 18 years+ - NCT07142096Recruiting
MitoQ before surgery for triple-negative breast cancer
This trial tests whether taking the supplement MitoQ before standard surgery can help treat triple-negative breast cancer. You would take MitoQ for a short time between diagnosis and surgery to see if it slows tumor growth.
BrusselsAges 18 years+ - NCT07117864Recruiting
T-DXd with brain radiation for HER2+ breast cancer
This trial tests a new combination of a targeted drug (T-DXd) with brain radiation for women with breast cancer that has spread to the brain and is HER2-positive or HER2-low. The goal is to see if this approach is safe and works better than radiation alone.
Beijing, Beijing MunicipalityAges 18–75 - NCT07116642Recruiting
Scar placement after breast-conserving surgery for breast cancer
This study compares how different scar placements after breast-conserving surgery affect your recovery and quality of life. By joining, you help doctors learn which scar location leads to the best outcomes for patients like you.
Leeds, West YorkshireAges 18 years+ - NCT07122713Recruiting
Radiation therapy for inoperable breast cancer
This trial tests whether definitive radiation therapy can effectively treat breast cancer that cannot be surgically removed. It may be an option for people whose cancer is inoperable or who choose not to have surgery.
Stony Brook, New YorkAges 18 years+ - NCT07111728Recruiting
Checking tumor margins during breast cancer surgery
This study tests a new imaging tool that helps surgeons see if any cancer cells are left behind during a lumpectomy. It may reduce the need for a second surgery.
Pavia, LombardyAges 18–85 - NCT07106632RecruitingPhase 3
Genomic test to guide chemotherapy in young women with breast cancer
This trial uses a genomic test called Prosigna to help decide whether young women with hormone-sensitive breast cancer need chemotherapy after surgery. It aims to avoid unnecessary chemotherapy in those who can safely skip it.
BrusselsAges 35–45 - NCT07102381RecruitingPhase 2
Zanidatamab plus chemo before surgery for HER2+ breast cancer
This trial tests a new drug called zanidatamab combined with chemotherapy to shrink HER2-positive breast cancer before surgery. It may help improve treatment outcomes for people with stage 2 or 3 breast cancer that has not spread.
Long Beach, CaliforniaAges 18 years+ - NCT07095023Recruiting
Oral chemo and targeted therapy before breast cancer surgery
This trial tests a combination of an oral chemotherapy pill (paclitaxel) with two targeted antibodies (pertuzumab and trastuzumab) given before surgery for HER2-positive breast cancer. The goal is to shrink the tumor and make surgery more effective.
Beijing, Beijing MunicipalityAges 18–75 - NCT03201861RecruitingPhase 3
Cisplatin added after surgery for high-risk breast cancer
This trial checks whether adding cisplatin to standard chemotherapy after surgery helps women with high-risk early-stage breast cancer lower the chance of the cancer coming back. You would be followed to see how well treatment works and whether it is tolerated.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT07076485RecruitingPhase 2
Shorter radiation after surgery for node-positive breast cancer
This trial tests shorter radiation schedules for people with breast cancer that has spread to lymph nodes or is high-risk. It aims to find a shorter course of radiation that is just as effective after surgery.
Loveland, ColoradoAges 18 years+ - NCT07071038RecruitingPhase 2
Switching medication to relieve side effects from aromatase inhibitors
This trial tests whether switching to a different aromatase inhibitor or using standard treatments works better for managing side effects in breast cancer survivors. It aims to help you stay on hormone therapy longer with fewer discomforts.
Lebanon, New HampshireAges 18 years+ - NCT07071272Recruiting
Comparing two breast imaging methods before surgery
This trial compares a special mammogram with dye (CEDM) to MRI for women already diagnosed with invasive breast cancer. The goal is to see if CEDM works as well as MRI for planning surgery, potentially offering a faster or easier option.
Verona, ItalyAges 30 years+ - NCT07057427RecruitingPhase 3
Nab-paclitaxel vs TCbHP for HER2-positive early breast cancer
This trial compares two different drug combinations given before surgery to shrink HER2-positive breast cancer tumors. The goal is to see which combination works better and has fewer side effects.
Zhengzhou, HenanAges 18–70 - NCT07054190RecruitingPhase 2
Testing inavolisib for early-stage PIK3CA-mutated breast cancer
This study tests a new drug called inavolisib for people with early-stage breast cancer that has a specific genetic change (PIK3CA mutation). The goal is to see if adding this drug to standard hormone therapy is safe and effective before surgery.
Los Angeles, CaliforniaAges 18 years+
Hear when a new Breast Cancer Invasive trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for breast cancer invasive?
- Yes. Clin2 currently lists 717 recruiting breast cancer invasive studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a breast cancer invasive trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a breast cancer invasive trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.